Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shilpa MedicareNSE:SHILPAMED +2.26%73 3-Year EBITDA Growth Rate is 53.40% as of Jun. 2026, which is 434% above its 10-year median of 10.00. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 73/100 and a GF Value™ of ₹456.70 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 808 Drug Manufacturers companies, Shilpa Medicare ranks better than 89.36% on this metric.
During the past 12 months, Shilpa Medicare's average EBITDA Per Share Growth Rate was 59.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 53.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 4.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shilpa Medicare was 57.10% per year. The lowest was -23.30% per year. And the median was 10.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Shilpa Medicare 3-Year EBITDA Growth Rate Related Terms
NSE:SHILPAMED vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 53.40% mean?
Shilpa Medicare (NSE:SHILPAMED) has a 3-Year EBITDA Growth Rate of 53.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Shilpa Medicare and its competitors. This is 434% above median its historical median of 10.00. According to the industry distribution chart, Shilpa Medicare ranks #86 out of 808 companies in the Drug Manufacturers industry, placing it in the top 10.6%.
Is Shilpa Medicare's 3-Year EBITDA Growth Rate too high?
Shilpa Medicare's current 3-Year EBITDA Growth Rate of 53.40% is 434% above median its 10-year median of 10.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Shilpa Medicare's value of 53.40% is 500% above this industry median. Based on the distribution chart, Shilpa Medicare ranks #86 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shilpa Medicare has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #86 out of 808 companies for 3-Year EBITDA Growth Rate. This places Shilpa Medicare in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Shilpa Medicare's value of 53.40% is 500% above this benchmark. While the company's 10-year median is 10.00 vs. the industry median of 8.90, Shilpa Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shilpa Medicare's current 3-Year EBITDA Growth Rate of 53.40% is 500% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Shilpa Medicare and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current 3-Year EBITDA Growth Rate is 53.40%, which is 434% above median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹456.70, compared to a current price of ₹961.15 — trading 110.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 53.40%, which is 434% above median its 10-year median of 10.00 and 500% above the Drug Manufacturers industry median of 8.90. Shilpa Medicare's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current 3-Year EBITDA Growth Rate is 53.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹961.15 is trading 110.5% above its estimated GF Value™ of ₹456.70.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for NSE:SHILPAMED:
3-Year EBITDA Growth Rate: 53.40% (434% above median its 10-year median of 10.00)
GF Value™: ₹456.70 vs. price of ₹961.15 (110.5% above fair value)
Industry Position: 500% above the Drug Manufacturers median (#86 of 808)
No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
73GF Score
Get the complete analysis for NSE:SHILPAMED
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SHILPAMED has been successfully added to your 
